LongeVC managing partner Sergey Jakimov and operating partner Artem Trotsyuk spoke with Brian Buntz of R&D World about what separates credible longevity companies from the noise, and how two of our portfolio companies exemplify this shift. Rubedo Life Sciences is targeting senescent cells through inflammatory skin conditions, beginning with plaque psoriasis, a clear indication with conventional endpoints and an established regulatory pathway. Unnatural Products Inc. is developing macrocyclic peptides and has already closed three pharma deals since LongeVC invested.
The throughline: genuine scientific innovation packaged within frameworks that pharma and regulators already understand.
Read the full article by Brian Buntz in R&D World here.
The throughline: genuine scientific innovation packaged within frameworks that pharma and regulators already understand.
Read the full article by Brian Buntz in R&D World here.